Kaituo Pharmaceuticals-B (09939) issued an announcementaxiecryptogame, its independently developed KX-826 tincture, potentially the first of its kindaxiecryptogameA clinical trial of.0% for the treatment of androgenic hair loss in Chinese adult men has recently been approved by the State Food and Drug Administrationaxiecryptogame, used to evaluate KX-826 tincture 1axiecryptogameEffectiveness and safety of 0% topical treatment in Chinese adult male patients with AGA. The company's preclinical research shows that compared with the 0.5% formulation of KX-826 tincture used in previous Phase III clinical trials, the retained concentration of this tincture 1.0% formulation on human scalp cells has been significantly increased, which is expected to improve clinical effects.
KX-826 is one of the group's core drugs. Since its development, it has completed many clinical trials for the treatment of hair loss in men and women in China and the United States, and has shown excellent safety and effectiveness trends. The group will further explore the therapeutic effect of KX-826 in the field of hair loss. At the same time, the group is conducting and planning to launch a number of clinical trials of KX-826 for the treatment of hair loss and acne, and continues to develop the value of KX-826 in the dermatology field.